- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 2.1 Exhibit 2.1
- 2.2 Exhibit 2.2
- 2.3 Exhibit 2.3
- 2.4 Exhibit 2.4
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 3.3 Exhibit 3.3
- 4.1 Exhibit 4.1
- 4.2 Exhibit 4.2
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 10.11 Exhibit 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.14 Exhibit 10.14
- 10.15 Exhibit 10.15
- 10.16 Exhibit 10.16
- 10.17 Exhibit 10.17
- 10.18 Exhibit 10.18
- 10.19 Exhibit 10.19
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 10.23 Exhibit 10.23
- 10.24 Exhibit 10.24
- 10.25 Exhibit 10.25
- 10.26 Exhibit 10.26
- 10.27 Exhibit 10.27
- 10.28 Exhibit 10.28
- 10.29 Exhibit 10.29
- 10.30 Exhibit 10.30
- 10.31 Exhibit 10.31
- 10.32 Exhibit 10.32
- 10.33 Exhibit 10.33
- 10.34 Exhibit 10.34
- 10.35 Exhibit 10.35
- 10.36 Exhibit 10.36
- 10.37 Exhibit 10.37
- 10.38 Exhibit 10.38
- 10.39 Exhibit 10.39
- 10.40 Exhibit 10.40
- 10.41 Exhibit 10.41
- 10.42 Exhibit 10.42
- 10.43 Exhibit 10.43
- 10.44 Exhibit 10.44
- 10.45 Exhibit 10.45
- 10.46 Exhibit 10.46
- 10.47 Exhibit 10.47
- 10.48 Exhibit 10.48
- 10.49 Exhibit 10.49
- 10.50 Exhibit 10.50
- 10.51 Exhibit 10.51
- 10.52 Exhibit 10.52
- 10.53 Exhibit 10.53
- 10.54 Exhibit 10.54
- 10.55 Exhibit 10.55
- 10.56 Exhibit 10.56
- 10.57 Exhibit 10.57
- 10.58 Exhibit 10.58
- 10.59 Exhibit 10.59
- 10.60 Exhibit 10.60
- 10.61 Exhibit 10.61
- 14.1 Exhibit 14.1
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- 32.2 Exhibit 32.2
Exhibit 10.4
AMENDMENT TO AGREEMENT
This AMENDMENT TO AGREEMENT is made effective as of this 1st day of May, 2005, by and between Biovail Laboratories International SRL, a Barbados International Society with Restricted Liability having a principal place of business at Chelston Park, Building 2, Collymore Rock, St. Michael, BH1, Barbados, W.I. (“Biovail”), and SmithKline Beecham Corporation, a GlaxoSmithKline company, a corporation duly organized and existing under the applicable laws of the Commonwealth of Pennsylvania having a principal place of business at One Franklin Plaza, Philadelphia, PA 19101 (“GSK”).
WHEREAS, the parties are parties to an Amended and Restated Distribution Rights Agreement (the “Agreement”) effective as of October 26, 2001; and
WHEREAS, the parties now desire to amend the Agreement,
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and other good and valuable consideration, the receipt and sufficiency of which are mutually acknowledged, GSK and Biovail agree as follows:
1. Effective as of the date set forth above, the definition of “Territory” set forth in Article 1 of the Agreement is hereby amended to add the United States Virgin Islands.
2. All other terms of the Agreement shall remain in full force and effect.
IN WITNESS WHEREOF, the parties have executed this Amendment to Agreement the day and year first above written.
SMITHKLINE BEECHAM CORPORATION |
| BIOVAIL LABORATORIES INTERNATIONAL SRL | ||
|
|
| ||
|
|
| ||
By: | /s/ Donald F. Parman |
| By: | /s/ John A.R. McCleery |
Title: | Vice President & Secretary |
| Title: | Vice President, General Manager |